Clinical and molecular characterization of familial hypocalciuric hypercalcemia in an endocrine practice: a case series of 25 patients

内分泌科临床中家族性低钙尿性高钙血症的临床和分子特征:25例病例系列研究

阅读:1

Abstract

Familial hypocalciuric hypercalcemia (FHH) is a disorder caused by abnormal sensing of calcium by the parathyroids and renal tubules and may mimic primary hyperparathyroidism (PHPT). Patients with FHH should not be subjected to unnecessary and potentially harmful parathyroid surgery. We sought to evaluate the clinical and biochemical presentation of FHH in our endocrine practice. This was a retrospective chart review done after Institutional Review Board approval. We describe 25 cases of likely FHH from our endocrine practice (20 FHH1, 1 FHH2, and 4 FHH3). The 24-h urinary calcium levels were often greater than 100 mg/24 h and sometimes greater than 200 mg/24 h. The calcium to creatinine clearance ratio (CCCR) was consistently <0.01 in 10 of 22 (45%). We also describe several variants of CASR and 1 variant of GNA11 that are probably pathogenic. Some patients, particularly FHH3 patients, have hypercalcemia severe enough to warrant treatment with a calcimimetic medication (cinacalcet). Traditional methods of excluding FHH using 24-h urinary calcium and CCCR are not adequate to distinguish FHH and PHPT. In addition to young age, family history of hypercalcemia and low CCCR, we believe molecular testing should be considered prior to surgery when hypercalcemia cannot be demonstrated to be acquired and in the case of persistent PHPT after surgery by an experienced parathyroid surgeon.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。